TLSA

0.62527.46%
RK

Richard K. Kim

Chief Medical Officer

Dr. Richard K. Kim, MD is Chief Medical Officer of Tiziana Life Sciences Ltd from 2026. He served as Chief Medical Officer and Senior Vice President of Clinical Development & Medical Affairs at Xenoport, Inc. since January 2014 until October 2016. Dr. Kim joined XenoPort in July 2013 as Vice President of Medical Affairs, supporting XenoPort's launch of HORIZANT (gabapentin enacarbil) Extended-Release Tablets. He has more than a decade of experience in both clinical development and medical affairs, most recently as vice president of clinical development and head of the multiple sclerosis therapeutic area at Elan Pharmaceuticals, Inc. In his previous position at Elan, Dr. Kim was joint program team leader for natalizumab (TYSABRI), which is approved globally for treatment of multiple sclerosis and approved for treatment of Crohn's Disease in the United States. Prior to Elan, he was the global medical affairs director for natalizumab at Biogen Idec Inc., during which he played an integral role in successfully re-launching TYSABRI in the United States, as well as its subsequent global launch. Prior to Biogen Idec, he served as Medical Director responsible for the cladribine Phase 3 program at EMD Serono, Inc. He began his industry career more than a decade ago at Purdue Pharma L.P., where he worked on the early development of buprenorphine transdermal patch (BUTRANS). Dr. Kim received his Medical Degree in Medicine from Tulane University, completed his neurology residency training at Stanford University and is a diplomat of the American Board of Psychiatry and Neurology. Dr. Kim holds Bachelor of Science in Biology from University of California, Los Angeles.

公司职务